These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1344751)

  • 1. A long term clinical trial of carteolol in the management of glaucoma. Belgian Carteolol Study Participants.
    Vercruysse K; Goethals M; Vandeputte O; Missotten L
    Bull Soc Belge Ophtalmol; 1992; 245():75-80. PubMed ID: 1344751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The influence of carteolol and pentoxyphylin on the visual field in glaucoma patients--case reports of selected patients].
    Machů V
    Cesk Slov Oftalmol; 2010 Feb; 66(1):39-42. PubMed ID: 20521510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study].
    Trinquand C; Romanet JP; Nordmann JP; Allaire C;
    J Fr Ophtalmol; 2003 Feb; 26(2):131-6. PubMed ID: 12660585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Carteolol: general practice-oriented assessment of the effectiveness and tolerance of a new beta-blocker in the treatment of glaucoma].
    Schnaudigel OE; Becker H; Fuchs HB
    Klin Monbl Augenheilkd; 1988 Mar; 192(3):248-51. PubMed ID: 3374015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension.
    Henness S; Swainston Harrison T; Keating GM
    Drugs Aging; 2007; 24(6):509-28. PubMed ID: 17571916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Carteolol in the treatment of open-angle glaucoma].
    Gorgone G; Randazzo S; Spina F
    Ophtalmologie; 1988; 2(5):431-3. PubMed ID: 3244464
    [No Abstract]   [Full Text] [Related]  

  • 7. Additive effect of dorzolamide or carteolol to latanoprost in primary open-angle glaucoma: a prospective randomized crossover trial.
    Maruyama K; Shirato S
    J Glaucoma; 2006 Aug; 15(4):341-5. PubMed ID: 16865013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypotensive effect of carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis.
    Ohno S; Ichiishi A; Matsuda H
    Ophthalmologica; 1989; 199(1):41-5. PubMed ID: 2761985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Influence on ocular surface and intraocular pressure of switching from preservative-containing to preservative-free carteolol hydrochloride ophthalmic solution].
    Chikama T; Araie M; Nishida T
    Nippon Ganka Gakkai Zasshi; 2013 May; 117(5):419-26. PubMed ID: 23855234
    [No Abstract]   [Full Text] [Related]  

  • 10. [Aqueous humor flow measured by fluorophotometry. A comparative study of the effect of various beta-blocker eyedrops in patients with ocular hypertension].
    Coulangeon LM; Sole M; Menerath JM; Sole P
    Ophtalmologie; 1990; 4(2):156-61. PubMed ID: 2235007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-center, 4-year, open-label study.
    Martínez A; Sánchez M
    Clin Ther; 2008 Jun; 30(6):1120-34. PubMed ID: 18640468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of topical carteolol on visual function in normal-tension glaucoma].
    Maeda H; Tanaka Y; Yamamoto M; Mizokami K
    Nippon Ganka Gakkai Zasshi; 1997 Mar; 101(3):227-31. PubMed ID: 9086741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
    Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
    Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypotensive action of 0.5% carteolol versus 0.1% timolol in patients with intraocular hypertension].
    Allaire C; Trinquand C; Nordmann JP; Dascotte JC; George JL; Lesure P; Rouland JF; Khaitrine L; Sirbat D
    J Fr Ophtalmol; 1995; 18(1):22-6. PubMed ID: 7738291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of beta-blocking agent carteolol on healthy volunteers and glaucoma patients (author's transl)].
    Negishi C; Ueda S; Kanai A; Nakajima A; Funahashi M; Kitazawa Y; Komemushi S
    Nippon Ganka Gakkai Zasshi; 1981 Jan; 85(1):57-66. PubMed ID: 6114632
    [No Abstract]   [Full Text] [Related]  

  • 16. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression.
    Schmier JK; Halpern MT; Covert DW; Robin AL
    Curr Med Res Opin; 2006 Sep; 22(9):1737-43. PubMed ID: 16968577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual field and intraocular pressure asymmetry in the low-pressure glaucoma treatment study.
    Greenfield DS; Liebmann JM; Ritch R; Krupin T;
    Ophthalmology; 2007 Mar; 114(3):460-5. PubMed ID: 17141318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ocular carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension.
    Chrisp P; Sorkin EM
    Drugs Aging; 1992; 2(1):58-77. PubMed ID: 1554974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Latanoprost therapy in patients with glaucoma and ocular hypertension inadequately controlled with carteolol.
    Yasar T; Ozdemir M; Andi I; Ozdemir G; Simsek S
    Jpn J Ophthalmol; 2004; 48(2):172-3. PubMed ID: 15060799
    [No Abstract]   [Full Text] [Related]  

  • 20. Remission of mild to moderate hypertension after treatment with carteolol, a beta-adrenoceptor blocker with intrinsic sympathomimetic activity.
    Giles TD; Sander GE; Roffidal L; Thomas MG; Mersch DP; Moyer RR; Burris JF; Mroczek WJ; Brachfeld J
    Arch Intern Med; 1988 Aug; 148(8):1725-8. PubMed ID: 3041936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.